MX2021012903A - Moduladores de la via de respuesta integrada al estres. - Google Patents

Moduladores de la via de respuesta integrada al estres.

Info

Publication number
MX2021012903A
MX2021012903A MX2021012903A MX2021012903A MX2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A
Authority
MX
Mexico
Prior art keywords
sup
stress response
modulators
integrated stress
response pathway
Prior art date
Application number
MX2021012903A
Other languages
English (en)
Inventor
Christopher Francis Palmer
Christopher John Brown
Daryl Simon Walter
Holly Atton
James Lindsay Carr
Serge Convers-Reignier
Michael Corr
Marissa Flower
Mohamad Sabbah
Scott Sadler
Jonathan Shine
Irena Doly Reboule
Original Assignee
Evotec Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Int Gmbh filed Critical Evotec Int Gmbh
Publication of MX2021012903A publication Critical patent/MX2021012903A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a los compuestos de la fórmula (I) (ver Fórmula) o sales farmacéuticamente aceptables, solvatos, hidratos, tautómeros o estereoisómeros de los mismos, en donde R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 y A2 tienen el significado que se indica en la descripción y en las reivindicaciones. La invención se refiere además a composiciones farmacéuticas que comprenden dichos compuestos, su uso como medicamento y a un método para tratar y prevenir una o más enfermedades o trastornos asociados con la respuesta integrada al estrés.
MX2021012903A 2019-04-23 2020-04-22 Moduladores de la via de respuesta integrada al estres. MX2021012903A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19170504 2019-04-23
EP19216875 2019-12-17
PCT/EP2020/061150 WO2020216766A1 (en) 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway

Publications (1)

Publication Number Publication Date
MX2021012903A true MX2021012903A (es) 2022-01-18

Family

ID=70289816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012903A MX2021012903A (es) 2019-04-23 2020-04-22 Moduladores de la via de respuesta integrada al estres.

Country Status (15)

Country Link
US (1) US20220227747A1 (es)
EP (1) EP3959198A1 (es)
JP (1) JP2022530049A (es)
KR (1) KR20220004105A (es)
CN (1) CN113993850B (es)
AU (1) AU2020261234A1 (es)
BR (1) BR112021020402A2 (es)
CA (1) CA3137213A1 (es)
CL (1) CL2021002772A1 (es)
CO (1) CO2021014292A2 (es)
IL (1) IL287379A (es)
MX (1) MX2021012903A (es)
PE (1) PE20220961A1 (es)
SG (1) SG11202111119PA (es)
WO (1) WO2020216766A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200110650A (ko) 2017-12-13 2020-09-24 프락시스 바이오테크 엘엘씨 통합된 스트레스 반응 경로의 억제제
EP3801522A4 (en) 2018-06-05 2022-06-01 Praxis Biotech LLC INTEGRATED STRESS RESPONSE PATHWAY INHIBITORS
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
US20230129907A1 (en) 2020-03-11 2023-04-27 Evotec International Gmbh Modulators of the integrated stress response pathway
MX2023004626A (es) 2020-10-22 2023-05-23 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
MX2023004623A (es) 2020-10-22 2023-05-12 Evotec Int Gmbh Moduladores de la via integrada de respuesta al estres.
KR20230110510A (ko) 2020-10-22 2023-07-24 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
WO2022212902A1 (en) * 2021-04-02 2022-10-06 Altos Labs, Inc. Modulators of integrated stress response pathway

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
JP6291601B2 (ja) * 2014-07-04 2018-03-14 ルピン・リミテッド Ｐｉ３ｋ阻害剤としてのキノリジノン誘導体
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
AU2017279027A1 (en) * 2016-06-08 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
US20190298705A1 (en) * 2016-06-08 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
BR112020000086A2 (pt) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças
JP2020525513A (ja) 2017-07-03 2020-08-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物
SG11202000532SA (en) 2017-08-09 2020-02-27 Denali Therapeutics Inc Compounds, compositions and methods
JP7382308B2 (ja) * 2017-09-01 2023-11-16 デナリ セラピューティクス インコーポレイテッド 化合物、組成物、及び、方法
BR112020008833A2 (pt) 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
MX2020004557A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
CA3080808A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3704089B1 (en) 2017-11-02 2023-07-19 Calico Life Sciences LLC Modulators of the integrated stress pathway
WO2019090082A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
WO2019090090A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
KR20200110650A (ko) 2017-12-13 2020-09-24 프락시스 바이오테크 엘엘씨 통합된 스트레스 반응 경로의 억제제
WO2019183589A1 (en) * 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors

Also Published As

Publication number Publication date
CN113993850B (zh) 2024-03-29
US20220227747A1 (en) 2022-07-21
CO2021014292A2 (es) 2022-04-29
IL287379A (en) 2021-12-01
EP3959198A1 (en) 2022-03-02
CN113993850A (zh) 2022-01-28
BR112021020402A2 (pt) 2021-12-07
JP2022530049A (ja) 2022-06-27
WO2020216766A1 (en) 2020-10-29
PE20220961A1 (es) 2022-06-10
AU2020261234A1 (en) 2021-11-11
CA3137213A1 (en) 2020-10-29
CL2021002772A1 (es) 2022-07-29
SG11202111119PA (en) 2021-11-29
KR20220004105A (ko) 2022-01-11

Similar Documents

Publication Publication Date Title
MX2021012903A (es) Moduladores de la via de respuesta integrada al estres.
MX2021012904A (es) Moduladores de la via de respuesta al estres integrada.
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MX2022009243A (es) Moduladores de la via de respuesta integrada al estres.
MX2020000261A (es) Nuevos compuestos.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2022005232A (es) Degradadores de moleculas peque?as de helios y procedimientos de uso.
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MX2021004940A (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
MX2022011143A (es) Moduladores de la via de respuesta integrada al estres.
CR20230143A (es) Degradadores de moléculas pequeñas de piperidinilo de helios y procedimientos de uso
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2021006095A (es) Pirazoles como moduladores de hemoglobina.
MX2023004623A (es) Moduladores de la via integrada de respuesta al estres.
MX2023004626A (es) Moduladores de la via de respuesta integrada al estres.